CRIS Current Research Information System

DE GIGLIO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 797
AS - Asia 631
EU - Europa 617
AF - Africa 58
SA - Sud America 4
OC - Oceania 2
Totale 2.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 795
IT - Italia 282
SG - Singapore 252
CN - Cina 167
IN - India 88
SE - Svezia 84
IE - Irlanda 64
JO - Giordania 47
VN - Vietnam 45
DE - Germania 44
FI - Finlandia 28
CH - Svizzera 27
TG - Togo 26
BG - Bulgaria 23
GB - Regno Unito 23
CI - Costa d'Avorio 22
ID - Indonesia 17
NL - Olanda 16
NG - Nigeria 10
HK - Hong Kong 7
ES - Italia 6
RU - Federazione Russa 4
PL - Polonia 3
UA - Ucraina 3
AT - Austria 2
AU - Australia 2
BR - Brasile 2
CA - Canada 2
GR - Grecia 2
JP - Giappone 2
LU - Lussemburgo 2
PK - Pakistan 2
TR - Turchia 2
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CO - Colombia 1
DK - Danimarca 1
FR - Francia 1
IL - Israele 1
PH - Filippine 1
Totale 2.109
Salva come PNG Salva come JPEG
Città #
Singapore 230
Santa Clara 193
Boardman 77
Hyderabad 66
Dublin 64
Ashburn 63
Chandler 59
Bologna 51
Amman 47
Seattle 38
Milan 33
Dong Ket 30
Lomé 26
Bern 23
Helsinki 23
Sofia 23
Abidjan 22
Cinquefrondi 22
Fairfield 20
Princeton 19
Jakarta 17
Southend 17
Woodbridge 16
Messina 15
Beijing 14
Guangzhou 11
Los Angeles 11
Abeokuta 10
Cambridge 10
New York 10
Redmond 10
Turin 10
Houston 9
Shanghai 9
Wilmington 9
Moncalieri 7
San Diego 7
Cesena 6
Rome 6
Berlin 5
Florence 5
Verona 5
Falkenstein 4
Fontanelice 4
Foshan 4
Hong Kong 4
Lappeenranta 4
Modena 4
Seville 4
Wuhan 4
Ann Arbor 3
Baricella 3
Boydton 3
Breda 3
Bühl 3
Chongqing 3
Diamante 3
Ferrara 3
Jinan 3
Luco dei Marsi 3
Paola 3
Redwood City 3
Tianjin 3
Xi'an 3
Bisceglie 2
Cosenza 2
Des Moines 2
Dulles 2
Fulham 2
Fuyang 2
Istanbul 2
Jiangmen 2
Karachi 2
Kerken 2
Manchester 2
Monza 2
Naples 2
Nuremberg 2
Parma 2
Reggio Emilia 2
S. Pietro 2
Saitama 2
Shenyang 2
Tarragona 2
Toronto 2
Vienna 2
Warsaw 2
Washington 2
Weifang 2
Yueqing 2
Zhengzhou 2
Amsterdam 1
Anyang 1
Athens 1
Baoding 1
Bremen 1
Brussels 1
Buenos Aires 1
Carlentini 1
Casalecchio di Reno 1
Totale 1.485
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 194
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 96
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 73
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 72
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 70
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach 67
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 65
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 58
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 54
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 54
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 50
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 46
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 46
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 39
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 38
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 38
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 38
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 37
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 35
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 34
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 33
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 30
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies 30
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 29
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 28
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 27
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 26
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 26
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 25
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 23
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics 23
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 22
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 22
Antibody–drug conjugates for lung cancer in the era of personalized oncology 22
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 22
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 21
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 21
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 21
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 21
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 21
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 21
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 21
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 20
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 19
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 19
Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici) 19
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)) 19
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report 18
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 18
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 18
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 17
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 17
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 17
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 17
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 17
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 16
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program 16
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 16
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 15
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 15
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 15
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 15
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 14
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 14
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 14
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 13
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 13
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 12
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 12
Primary angiosarcoma of the kidney: Case report and comprehensive literature review 12
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives 10
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 10
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 10
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 10
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 10
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management 9
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 9
Totale 2.254
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021133 0 0 0 0 34 22 1 5 7 2 3 59
2021/2022174 3 2 1 4 8 6 0 37 20 10 53 30
2022/2023575 26 40 19 27 77 46 12 49 162 37 28 52
2023/2024395 36 47 26 25 23 73 9 62 16 25 39 14
2024/2025977 113 137 131 137 307 115 37 0 0 0 0 0
Totale 2.254